ClinicalTrials.gov
public full text
Public Domain
A Composite Assay for HER2-positive Early-stage Breast Cancer Management
The goal of this observational study is to assess the prognostic value of a genomic classifier (S18) and its refined version (S\*) in women with early-stage HER2-positive breast cancer. The study aims to determine whether these tools can predict event-free (EFS) and disease-free survival (DFS) in patients treated with neoadjuvant and/or adjuvant trastuzumab-based therapies.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- HER2-positive Breast Cancer Project Initiated by Investigators#1009213
- Factors influencing oncologists’ decisions for germline BRCA testing and adjuvant therapy selection in HER2-negative early breast cancer.#988621
- HER2 Vaccine for Locally Advanced Breast Cancer#148563
- Development and validation of a machine learning model to evaluate survival in patients with newly diagnosed breast cancer with liver metastasis.#330813
- Genetic Assessment of Breast Cancer Risk in Women in the DORA Programme#978938
Record · ID 880189
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive